• AT13387 and NINJ1: Evidence Gaps Across Domains

  2026-10-12

  AT13387 is described by APExBIO as an Hsp90 inhibitor for cancer biology research, whereas Song et al. investigated NINJ1-dependent norovirus protein secretion. The supplied evidence does not establish a mechanistic or therapeutic connection between these domains, so cross-domain claims should be treated as hypotheses rather than findings.

• HyperScribe T7 Cy3 Kit: Scope and Evidence

  2026-10-12

  The HyperScribe™ T7 High Yield Cy3 RNA Labeling Kit Plus is documented as an APExBIO research-use kit for producing randomly Cy3-modified RNA through T7-based in vitro transcription. Its stated conceptual scope includes fluorescent RNA detection, RNA probe synthesis for in situ hybridization, and Northern blot RNA probe labeling. No matched research paper or independent performance dataset was supplied, so product claims should not be treated as demonstrated comparative outcomes or clinical evidence.

• Standardized Whole-Blood Stimulation in Immunometabolism

  2026-10-10

  Zhao and colleagues present a standardized whole-blood stimulation framework for examining how metabolic interventions reshape cytokine responses to innate immune stimuli. The protocol’s main contribution is methodological: it connects immunometabolic perturbation with scalable functional immune profiling while emphasizing controls, cytokine measurement, and limits on interpretation.

• JZL184: Evidence, Mechanism, and Limits

  2026-10-09

  JZL184 is a research compound used to perturb monoacylglycerol lipase and 2-arachidonoylglycerol signaling. This overview addresses five questions about its biological principle, findings in a 2025 mouse traumatic brain injury study, evidence quality, interpretation, and limits of applicability. It separates reported results from mechanistic inference and avoids treating preclinical pharmacology as a therapeutic recommendation.

• Tacrolimus (FK506): Mechanism and Evidence

  2026-10-09

  A source-grounded overview of Tacrolimus (FK506) in T-cell signaling, transplantation immunology research, and immune response suppression, with emphasis on mechanism, evidence comparison, conceptual applications, and the limitations of extrapolating cyclosporine findings to FKBP12-dependent calcineurin inhibition.

• Evacetrapib and the Ferroptosis Frontier

  2026-10-08

  A translational perspective on how the H2S–SAHH–homocysteine axis reshapes ferroptosis research, and where Evacetrapib (LY2484595) may serve as a hypothesis-driven research probe rather than a validated ferroptosis therapy.

• AY 9944 Dihydrochloride: DHCR7 Research Evidence

  2026-10-08

  A source-grounded overview of AY 9944 dihydrochloride, DHCR7 biology, sterol perturbation research, and recent evidence connecting Dhcr7 disruption with antiviral resistance in grass carp.

• SP2509 and the Logic of Epigenetic Co-Targeting

  2026-10-07

  SP2509 is a potent Lysine-specific demethylase 1 antagonist for studying histone H3K4 regulation in acute myeloid leukemia. This article places its AML findings in a broader evidence framework informed by a BRD4–RAC1 breast cancer study, emphasizing mechanism, model boundaries, and rational interpretation rather than promotional claims.

• Live-Dead Bacterial Staining Kit: Beyond Green/Red

  2026-10-07

  The Live-Dead Bacterial Staining Kit can provide a membrane-integrity view of bacterial injury, but its signals require careful interpretation. This article connects NucGreen dye and EthD-III readouts with the Fe3O4@ZIF-8 jaw osteomyelitis study while defining evidence limits for nanomaterial research.

• Bortezomib and the mTORC1–UCK2 Axis

  2026-10-06

  Bortezomib (PS-341) is best understood not only as a reversible 20S proteasome inhibitor, but also as a tool for testing how protein turnover shapes pyrimidine metabolism. This article connects Bortezomib to the mTORC1–CTLH-WDR26–UCK2 pathway while emphasizing evidence boundaries, mechanistic controls, and translational relevance.

• PSPro Maps Spatial Proteomes at Single-Cell-Type Resolution

  2026-10-06

  Mao and colleagues introduce PSPro, a proximity-labeling strategy for capturing cell-type-associated proteomes directly from complex tissue slices. The study reports thousands of enriched proteins across ten cell types and shows that combining PSPro with laser microdissection can expose spatial proteome heterogeneity in pancreatic tumors.

• Angiotensin (1-7): ACE2 Evidence in Context

  2026-10-05

  Angiotensin (1-7) is more than a counter-regulatory renin–angiotensin peptide: its interpretation depends on separating Mas receptor biology from ACE2 enzymology. This evidence-focused guide explains the peptide sequence, signaling framework, assay limitations, and translational boundaries for research.

• CARDIO Reveals HSPB7 Rescue in Titin Cardiomyopathy

  2026-10-05

  Chopra and colleagues describe CARDIO, a high-content morphological profiling platform for human stem cell-derived cardiomyocytes, and use it to connect gene perturbations with cardiac cell phenotypes. The study reports that HSPB7 loss produced a hypertrophic phenotype and restored contractile function in a titin cardiomyopathy model, while also showing how morphology-based screening can nominate genes for functional follow-up.

• Metformin HCl: Reading HO Evidence

  2026-10-04

  Metformin Hydrochloride is more than a metabolic research tool: its effects on heterotopic ossification illustrate how pathway, cell, and animal evidence should be interpreted together. This article evaluates the Nr4a1/Wnt/β-catenin findings, translational boundaries, and priorities for stronger mechanistic studies.

• Angiotensin I/II (1-5): Product Overview

  2026-10-03

  APExBIO lists Angiotensin I/II (1-5), SKU A1047, as an Asp-Arg-Val-Tyr-Ile peptide fragment associated conceptually with renin-angiotensin system research. No matched paper evidence is available for product-specific performance or outcomes.

7951 records 1/531 page Next 12345 下5页 Last page